Berna maintained by Merrill at neutral

Berna Biotech was maintained by Merrill Lynch analyst Peter Welford at a neutral rating following news of a licensing deal with Solvay to market its cystic fibrosis vaccine Aerugen in the United States and other non-EU countries. Berna shares on the Xetra on Tuesday were up €0.29, or 4.65%, at €6.52.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.